Application of swertia mileensis extract in whitening and / or yellow removing

Abstract

The invention discloses application of swertia mileensis extract in whitening and / or yellowing removal, and belongs to the technical field of daily chemical products. The application of the swertia mileensis extract in whitening and / or yellow removing is provided for the first time, for example, the swertia mileensis extract can effectively inhibit melanogenesis of B16-F10 cells and improve the ITA degree value of human skin, and therefore the whitening effect is achieved; in addition, the swertia mileensis extract can promote expression of a bilirubin metabolism related gene UGT1A1 of HaCaT cells, and the yellow removing effect is achieved by promoting bilirubin metabolism. Moreover, the swertia mileensis extract can also reduce the content of bilirubin in the skin, reduce the redness a * value and the yellowness b * value of the skin and improve the brightness L * value of the skin, so that the effect of removing the yellowness is achieved. In other words, the swertia mileensis extract can effectively solve the problems of skin pigmentation, darkness, yellowing and the like, and has a great application prospect in preparation of daily chemical products and / or drugs with whitening and / or yellowing removing effects.

Description

Technical Field

[0001] The invention relates to the technical field of daily chemical products, and in particular to application of a green leaf gall extract in whitening and / or removing yellowing. Background Art

[0002] With the development of economy and the improvement of living standards, consumers' demand for skin beauty is growing, especially the demand for whitening and yellowing removal has increased significantly. Whitening is not only for the pursuit of brighter skin color, but also an important manifestation of modern people's pursuit of healthy and youthful appearance. Yellowing removal targets the dullness and yellowing problems caused by internal and external factors, helping consumers achieve a more even and vibrant skin color. Therefore, active ingredients with dual whitening and yellowing effects are highly favored in the skin care market and have become a hot spot for research and development.

[0003] Common whitening active ingredients include hydroquinone, vitamin C, kojic acid and arbutin, which mainly work by inhibiting tyrosinase activity, anti-oxidation and blocking melanin transmission. However, these traditional whitening ingredients have limitations: for example, although hydroquinone has a significant whitening effect, long-term use can easily cause skin irritation, allergies and even pigment abnormalities; vitamin C has poor stability and is easily oxidized; kojic acid and arbutin may cause sensitivity when used in high concentrations. In addition, despite the strong demand in the whitening market, there are relatively few effective solutions for the problem of yellowing skin.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] The object of the present invention is to provide an application of a green leaf gall extract in whitening and / or removing yellowing, so as to solve or improve the above technical problems.

[0006] The present invention can be implemented like this:

[0007] In a first aspect, the present invention provides a use of a green leaf gall extract in whitening and / or removing yellowing.

[0008] In an alternative embodiment, the Herba Lycopodii extract is used to inhibit melanin production.

[0009] In an alternative embodiment, the green leaf gall extract is used to increase the expression of the UGT1A1 gene.

[0010] In an alternative embodiment, the Herba Lycopodii extract is used to reduce bilirubin levels in the skin.

[0011] In an alternative embodiment, the Herba Lycopodii extract is used to reduce the yellowness b* value of the skin.

[0012] In an alternative embodiment, the Herba Lycopodii extract is used to reduce the redness a* value of the skin.

[0013] In an alternative embodiment, the extract of Glechoma longituba is used to increase the lightness L* value of the skin.

[0014] In an alternative embodiment, the extract of Glechoma longituba is used to increase the ITA° value of the skin.

[0015] In an optional embodiment, the effective concentration of the green leaf gall extract is 0.01wt% to 5wt%.

[0016] In an optional embodiment, the effective concentration of the green leaf gall extract is 0.01wt% to 0.2wt%.

[0017] In an optional embodiment, the preparation of the green leaf gall extract includes: extracting the crushed green leaf gall leaves with an organic solvent; wherein the organic solvent is an ethanol-water solution with an ethanol concentration of 65% to 75%, the ratio of the organic solvent to the green leaf gall leaves is 8mL:1g to 12mL:1g, the extraction temperature is 48°C to 52°C, and the extraction time is 46h to 50h.

[0018] In a second aspect, the present invention provides a daily chemical product, which contains the green leaf gall extract.

[0019] In an optional embodiment, the daily chemical products include cosmetics.

[0020] In an optional embodiment, the cosmetic comprises skin care water, skin care milk, skin care cream, facial cleanser or hair care water.

[0021] In an optional embodiment, the dosage form of the daily chemical product includes a solution, a suspension, an emulsion, a lotion, a gel, an ointment, a paste, a spray or a patch.

[0022] In a third aspect, the present invention provides a medicine comprising a green leaf gall extract.

[0023] The beneficial effects of the present invention include:

[0024] The present invention proposes for the first time the use of the green leaf gall extract in whitening and / or removing yellowing. For example, the green leaf gall extract can effectively inhibit the melanin production of B16-F10 cells and increase the ITA° value of human skin, thereby achieving a whitening effect; in addition, the green leaf gall extract can promote the expression of the bilirubin metabolism-related gene UGT1A1 in HaCaT cells, and achieve the effect of removing yellowing by promoting bilirubin metabolism. In addition, the green leaf gall extract can also reduce the bilirubin content in the skin, reduce the redness a* value and yellowness b* value of the skin, and increase the skin brightness L* value, thereby achieving the effect of removing yellowing. In other words, the green leaf gall extract has both whitening and yellowing effects, and can effectively solve the problems of skin pigmentation, dullness and yellowing. It can not only meet the needs of consumers for uniform and bright skin color, but also effectively deal with the problems of dullness and yellowing, and enhance the overall competitiveness of related daily chemical products and / or medicines, and has broad market prospects and commercial value. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0026] Figure 1 The result diagram of the cytotoxicity experiment in Example 2;

[0027] Figure 2 This is a result diagram of the melanin inhibition experiment in Example 3;

[0028] Figure 3 This is a result diagram of the determination of the gene expression level of the bilirubin metabolism-related gene UGT1A1 in Example 4;

[0029] Figure 4 This is the result diagram of the skin bilirubin content in Example 5;

[0030] Figure 5 This is a result diagram of the skin brightness L* value in Example 5;

[0031] Figure 6 This is a result diagram of the skin redness a* value in Example 5;

[0032] Figure 7 This is a result diagram of the skin yellowness b* value in Example 5;

[0033] Figure 8 This is the result diagram of the skin ITA° value in Example 5. DETAILED DESCRIPTION

[0034] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0035] The application of the green leaf gall extract provided by the present invention in whitening and / or removing yellowing is specifically described below.

[0036] At present, the use of the green leaf gall extract is mainly used for clearing away heat and detoxification, promoting dampness and reducing swelling, inhibiting bacteria or tightening the skin. The present invention creatively provides a new use of the green leaf gall extract, specifically, the green leaf gall extract is used for whitening and / or removing yellowness.

[0037] In some embodiments, the extract of the green leaf gall is used to achieve a whitening effect; in other embodiments, the extract of the green leaf gall is used to achieve a yellowing effect; in other embodiments, the extract of the green leaf gall is used to achieve both whitening and yellowing effects.

[0038] In the present invention, the green leaf gall extract can be used to inhibit the production of melanin, thereby achieving a whitening effect.

[0039] In the present invention, the green leaf gall extract can also be used to increase the expression of the UGT1A1 gene. The UGT1A1 gene is a gene related to bilirubin metabolism in HaCaT cells. The green leaf gall extract can promote bilirubin metabolism by increasing the expression of the UGT1A1 gene, thereby reducing the bilirubin content in the skin and achieving the effect of removing jaundice.

[0040] In some embodiments, the extract of green leaf gall can be used to reduce the redness a* value of the skin; in some embodiments, the extract of green leaf gall can be used to reduce the yellowness b* value of the skin; in some embodiments, the extract of green leaf gall can be used to increase the brightness L* value of the skin; in some embodiments, the extract of green leaf gall can be used to increase the ITA° value of the skin. Among them, ITA° (Individual Typological Angle, ITA°) refers to the individual type angle, which is an indicator commonly used in skin color grading. The ITA angle is the position angle of the skin color of the measured individual in the geometric plane formed by the L* and b* values. The grade of the skin color is determined according to this angle. The larger the ITA angle, the lighter the skin color, and the smaller the ITA angle, the darker the skin color.

[0041] In some embodiments, the concentration of the green leaf gall extract can be 0.01wt% to 5wt%, such as 0.01wt%, 0.02wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.5wt%, 1wt%, 2wt%, 3wt%, 4wt% or 5wt%, etc., or other values ​​within the range of 0.01wt% to 5wt%. In some typical embodiments, the concentration of the green leaf gall extract is 0.01wt% to 0.2wt%.

[0042] Within the above-mentioned effective concentration range, it can achieve better whitening and anti-yellowing effects while ensuring safety.

[0043] In some optional embodiments, the preparation of the green leaf gall extract may include: extracting the crushed green leaf gall leaves with an organic solvent; wherein the organic solvent is an ethanol-water solution with an ethanol concentration of 65% to 75%, the ratio of the organic solvent to the green leaf gall leaves is 8mL:1g to 12mL:1g, the extraction temperature is 48°C to 52°C, and the extraction time is 46h to 50h.

[0044] In some typical embodiments, the preparation of the green leaf gall extract can be carried out according to the following method:

[0045] S1: Collect fresh or dried leaves from healthy and mature green leaf gall plants. If using dried leaves, make sure they are completely dry and free of mold.

[0046] S2: The collected green leaf gall leaves are crushed into fine powder to increase the surface area in contact with the solvent, thereby improving the extraction efficiency. Excessive heating should be avoided during the crushing process to protect the active ingredients in the leaves.

[0047] S3: Using 70wt% ethanol-water solution as solvent, the ratio of solvent to green leaf gall leaf is 10mL:1g, and extraction is carried out at 50℃ for 48h. This temperature condition can effectively extract the active ingredients in green leaf gall while avoiding the loss of heat-sensitive components. Mechanical stirring is used to keep the mixture uniform and improve the extraction efficiency.

[0048] S4: Use a bag filter to perform preliminary filtration on the extract obtained from the leaching to remove large solid particles, and then continue to use a precision filter membrane to carefully filter the filtrate after the preliminary filtration to ensure the purity of the extract.

[0049] S5: The filtrate obtained after fine filtration was concentrated using a rotary evaporator at 35°C, keeping the evaporation temperature low to prevent the decomposition of the active ingredient.

[0050] It should be noted that the green leaf gall extract in the present invention can also be a commercially available product (that is, directly purchased), or can be prepared by referring to the existing technology. Under the same action concentration, the green leaf gall extract prepared by the method provided by the present invention can simultaneously achieve better whitening and yellowing effects.

[0051] In continuation of the above, the present invention proposes for the first time the use of the green leaf gall extract in whitening and / or removing yellowing. For example, the green leaf gall extract can effectively inhibit the melanin production of B16-F10 cells and increase the ITA° value of human skin, thereby achieving a whitening effect; in addition, the green leaf gall extract can promote the expression of the bilirubin metabolism-related gene UGT1A1 in HaCaT cells, and achieve the effect of removing yellowing by promoting bilirubin metabolism. Moreover, the green leaf gall extract can also reduce the bilirubin content in the skin, reduce the b* value of the skin, and increase the L* value of the skin, thereby achieving the effect of removing yellowing. In other words, the green leaf gall extract has both whitening and yellowing effects, and can effectively solve the problems of skin pigmentation, dullness and yellowing. It can not only meet the needs of consumers for uniform and bright skin color, but also effectively deal with the problems of dullness and yellowing, and enhance the overall competitiveness of related daily chemical products and / or medicines, and has broad market prospects and commercial value.

[0052] In addition, the invention also provides a daily chemical product, which contains the green leaf gall extract.

[0053] In some optional embodiments, the daily chemical products include cosmetics, which may exemplarily but not limitatively include skin care water, skin care milk, skin care cream, facial cleanser or hair care water, etc. The dosage form of the above-mentioned daily chemical products may exemplarily but not limitatively include solutions, suspensions, emulsions, lotions, gels, ointments, pastes, sprays or patches, etc.

[0054] In addition, the invention also provides a medicine, which contains the green leaf gall extract.

[0055] The above-mentioned daily chemical products and medicines containing the green leaf gall extract can have certain whitening and yellowing removal effects.

[0056] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0057] Example 1

[0058] This embodiment provides a green leaf gall extract, and the preparation method thereof is as follows:

[0059] S1: Collect fresh or dried leaves from healthy and mature S. cerana plants.

[0060] S2: Grind the collected green leaf gall leaves into fine powder.

[0061] S3: Use ethanol-water solution with ethanol concentration of 70wt% as solvent, the ratio of solvent to green leaf gall leaf is 10mL:1g, and extract at 50℃ for 48h.

[0062] S4: Use a bag filter to perform preliminary filtration on the extract obtained from the leaching to remove large particles of solids, and then continue to use a precision filter membrane to finely filter the filtrate after the preliminary filtration.

[0063] S5: The filtrate obtained after the fine filtration was concentrated using a rotary evaporator at 35° C. to a solid content of 40 wt %.

[0064] Example 2

[0065] Cytotoxicity assay

[0066] (1) Cell plating

[0067] First, after B16-F10 cells (mouse melanoma cells) have grown in the culture dish, discard the old culture medium and wash it with 0.01 mol / L PBS buffer with a pH of 7.2, and then discard the PBS. Next, add 1 mL of trypsin to the culture dish and place it in a cell culture incubator (37°C, 5% CO2) to digest for about 1.5 minutes. After digestion, add 3 mL of DMEM complete culture medium to terminate the digestion reaction, and transfer the cells to a 15 mL centrifuge tube with a pipette and centrifuge at 1000 rpm for 5 minutes. After centrifugation, discard the supernatant, add 1 mL of fresh culture medium and gently suspend the cells with a pipette. Use a cell counter to quantify the density of the cells in the suspension. After determining the cell density, adjust the density of the cell suspension to 5×10 4 / mL, and inoculated into a 96-well plate at an inoculation volume of 100 μL / well. Finally, the 96-well plate was returned to a 37°C cell culture incubator for 24 hours.

[0068] (2) Administration

[0069] Dilute the green leaf gall extract to the required concentration with PBS buffer. Add 10 μL of the green leaf gall extract of different concentrations to each well of the sample group, and set 6 replicates for each concentration. At this time, the final concentration of the green leaf gall extract is 8%, 5%, 4%, 2%, 1%, 0.5%, 0.25% and 0.125%. Add 10 μL PBS buffer to the control group, and also set 6 replicates. After completion, place the 96-well plate in a cell culture incubator at 37°C and culture for 24 hours.

[0070] (3) Cell viability assay

[0071] First, mix the CCK-8 reagent with DMEM culture medium in a volume ratio of 1:10 to obtain the detection working solution. Then use a pistol to gently remove the old culture medium in the 96-well plate to avoid damage to the cells. Add 100 μL of detection working solution to each well. After the addition is completed, carefully place the well plate in a cell culture incubator at 37°C and incubate for about 1 hour to allow CCK-8 to fully react with the cells and form a detectable color change. After the incubation time is over, take out the 96-well plate and immediately use an ELISA reader for dual-wavelength measurement. Set the main wavelength to 450nm and the reference wavelength to 630nm. This dual-wavelength detection method can accurately evaluate the viability and proliferation status of the cells in the wells.

[0072] (4) Data analysis

[0073] After the test, the obtained data was analyzed. The calculation formula of cell viability is as follows:

[0074] Where As represents the absorbance of the sample group, and Ac represents the average absorbance of the control group.

[0075] The independent sample T test was used to analyze the significant differences between the sample treatment group and the control group. P < 0.05 was considered statistically significant, *P < 0.05, **P < 0.01.

[0076] (5) Experimental results

[0077] The results of cytotoxicity experiments were as follows Figure 1 As shown by Figure 1 It can be seen that within the concentration range of 0.125% to 8%, the green leaf gall extract has no cytotoxic effect on B16 cells.

[0078] Example 3

[0079] Melanin inhibition experiment

[0080] (1) Cell plating

[0081] B16-F10 cells were cultured at 15 × 10 4 The cells were inoculated into a 100 mm cell culture dish at a density of 100 / mL, with an inoculation volume of 10 mL / dish. After inoculation, the dish was placed in a 37°C cell culture incubator for 24 hours.

[0082] (2) Administration

[0083] The culture dishes were divided into the following nine groups: blank control group, positive control group, 0.01% Qingyedan ​​group, 0.05% Qingyedan ​​group, 0.1% Qingyedan ​​group, 0.2% Qingyedan ​​group, 0.5% Qingyedan ​​group, 1% Qingyedan ​​group and 5% Qingyedan ​​group, with three replicates in each group. Phenethylresorcinol (abbreviated as "377") was used as a positive control with a final concentration of 2ppm. After administration, the cells were placed in a 37°C cell culture incubator for 24h.

[0084] (3) Melanin content detection

[0085] Digest with trypsin and collect cells by centrifugation. After discarding the supernatant, wash the cells twice with PBS, discard the supernatant again, add 300 μL of 1 mol / L NaOH containing 10% DMSO, and place in an 80°C water bath for 30 minutes to lyse the cells. After lysis, take 200 μL of cell lysate to a 96-well plate, read the absorbance at 405 nm with an enzyme reader, and finally convert the absorbance into melanin content. The melanin content of the control group is set as 100%.

[0086] (4) Data analysis

[0087] After the test, the obtained data was analyzed. The calculation formula of melanin inhibition rate is as follows:

[0088] Where As represents the absorbance of the sample group, and Ac represents the average absorbance of the blank control group.

[0089] The independent sample T test was used to analyze the significant differences between the sample treatment group and the control group. P < 0.05 was considered statistically significant, *P < 0.05, **P < 0.01.

[0090] (5) Experimental results

[0091] Melanin inhibition test results Figure 2 As shown by Figure 2 It can be seen that within the concentration range of 0.01% to 5%, with the increase of concentration, the ability of the green leaf gall extract to inhibit the melanin of B16-F10 cells gradually increases. At concentrations of 0.01%, 0.05%, 0.1%, 0.2%, 0.5%, 1% and 5%, the melanin inhibition rates of B16-F10 cells were 3.9%, 6.7%, 9.6%, 11.7%, 12.0%, 14.0% and 17.8%, respectively, indicating that the green leaf gall extract has a good whitening effect.

[0092] Example 4

[0093] Determination of the expression level of UGT1A1 gene related to bilirubin metabolism

[0094] (1) Cell seeding

[0095] HaCaT cells (human immortalized keratinocytes) grown in 1640 complete medium were cultured at 15×10 4 The cells were inoculated at a density of 100 / mL in a 6-well cell culture plate, with 2 mL per well. After inoculation, the 6-well plate was placed in a cell culture incubator and cultured for 24 h.

[0096] (2) Administration

[0097] The experiment was divided into the following nine groups: blank control group, 0.01% Qingyedan ​​group, 0.05% Qingyedan ​​group, 0.1% Qingyedan ​​group, 0.2% Qingyedan ​​group, 0.5% Qingyedan ​​group, 1% Qingyedan ​​group and 5% Qingyedan ​​group, with 3 replicates in each group, and the blank control group was added with an equal volume of PBS. After administration, the 6-well plate was placed in a cell culture incubator for 24 hours.

[0098] (3) RNA extraction and cDNA synthesis

[0099] RNA was extracted using the TaKaRa MiniBEST Universal RNA Extraction Kit, and then PrimeScript was applied. TM The RT reagent Kit with gDNA Eraser synthesizes the extracted RNA into cDNA. The specific operation method is carried out according to the instructions of the kit.

[0100] (4) Detection of UGT1A1 gene expression

[0101] Using TB Premix Ex Taq TM The kit was used to detect the expression level of the UGTT1A1 gene, GAPDH was used as the internal reference gene, and the reaction system of fluorescence quantitative PCR was set to 10 μL. The specific loading method was referred to the instructions of the kit. After loading, the gene expression level was detected on the real-time fluorescence quantitative PCR system, and the reaction program was as follows: 95°C, 30s, 40 cycles (95°C, 5s, 54°C, 30s).

[0102] (5) Results statistics and analysis

[0103] The relative expression level of genes was calculated using the 2-ΔΔCt method. GraphPad Prism software was used for plotting, and the results of gene expression were expressed as Mean±SD. The significant difference between the two groups of data was analyzed using the independent sample T test.

[0104] (6) Experimental results

[0105] The results of the experiment on the expression level of UGT1A1 gene related to bilirubin metabolism are as follows Figure 3 As shown by Figure 3 It can be seen that: within the concentration range of 0.01% to 0.2%, with the increase of the concentration of green leaf gall extract, the UGT1A1 gene expression level of HaCaT cells gradually increased; within the concentration range of 0.2% to 5%, with the increase of the concentration of green leaf gall extract, the UGT1A1 gene expression level of HaCaT cells gradually decreased. Specifically, the increase rates of UGT1A1 gene expression at concentrations of 0.01%, 0.05%, 0.1%, 0.2%, 0.5%, 1%, and 5% of green leaf gall extract were 24.3%, 37.0%, 72.7%, 133.3%, 100.7%, 97.3%, and 92.0%, respectively, indicating that green leaf gall extract may have the effect of immediately removing jaundice by promoting bilirubin metabolism.

[0106] Example 5

[0107] Clinical efficacy testing

[0108] (1) Test samples

[0109] Test group: 0.2% of the green leaf gall extract (prepared with a base material), that is, 0.2% of the green leaf gall extract provided in Example 1 was added to the base material;

[0110] Blank control group: base material.

[0111] The composition and corresponding content of the base material are shown in Table 1.

[0112] Table 1 Base material composition and content

[0113] Ingredient name content water 90.32％ 1,3-Propanediol 6％ Dimethicone 2％ Pentaerythritol tetra(ethylhexanoate) 0.5％ Sodium polyacryloyldimethyl taurate 0.4％ p-Hydroxyacetophenone 0.4％ 1,2-Hexanediol 0.12％ Gellan Gum 0.08％ Phenoxyethanol 0.06％ Caprylyl Glycol 0.06％ Sodium dihydrogen phosphate 0.04％ Disodium hydrogen phosphate 0.02％ total 100％

[0114] (2) Test equipment

[0115] Skin color tester (Colorimeter CL400, CK, Germany), transcutaneous icterometer.

[0116] (3) Volunteers

[0117] A total of 35 volunteers participated in this project, including 31 effective volunteers, aged between 22 and 43 years old, with an average age of 29.13 years old, all of whom had Asian skin.

[0118] (4) Test environment

[0119] Test environment: temperature (21±1)℃, humidity (50±10)%, and real-time dynamic monitoring.

[0120] (5) Test time

[0121] Before use (D0), 15 minutes after use, the next morning after use, and 7 days after use (D7).

[0122] (6) Test process

[0123] ① Before use (D0)

[0124] After the volunteers arrived, they cleaned their faces with cleansing products, then sat in the test environment for 30 minutes without drinking hot water or beverages. After 30 minutes, the volunteers underwent skin color tests and transcutaneous icterometer tests on specific areas of their faces.

[0125] ②15min after use

[0126] During the first visit, volunteers underwent skin color testing and transcutaneous icterometer testing on specific areas of the face 15 minutes after using the product.

[0127] ③, The next morning after use (within 24 hours)

[0128] The volunteers came to the test the next morning after using the product and sat in the test environment for 30 minutes without drinking hot water or beverages. After 30 minutes, the volunteers underwent skin color testing and transcutaneous jaundice instrument testing on specific areas of their faces.

[0129] ④, 7 days after use (D7)

[0130] The volunteers used the product for 7 consecutive days before the visit. After the visit, they cleaned their faces with a cleansing product and then sat in the test environment for 30 minutes without drinking hot water or beverages. After 30 minutes, the volunteers underwent skin color testing and transcutaneous icterometer testing on specific areas of their faces.

[0131] (7) Data analysis

[0132] The calculation formula of the change rate is: change rate = (measurement value after use - measurement value before use) / measurement value before use × 100%.

[0133] The paired T test was used to analyze the significant differences between the sample treatment group and the control group. P < 0.05 was considered statistically significant, *P < 0.05, **P < 0.01.

[0134] (8) Experimental results

[0135] ① Skin bilirubin content

[0136] The raw data of skin bilirubin content determination are shown in Table 2 and Table 3. The results of skin bilirubin content are as follows Figure 4 As shown by Figure 4It can be seen that compared with before use, the bilirubin content of facial skin was significantly reduced after using 0.2% green leaf gall extract for 15 minutes, the next morning, and 7 days, with the reduction rates being 9.73%, 8.37%, and 11.54% respectively; while the bilirubin content of the control group had no significant changes at these three test time points. The above results show that green leaf gall extract can immediately reduce the bilirubin content of the skin and play an immediate role in removing jaundice.

[0137] Table 2 Bilirubin content in skin after using 0.2% green leaf bile extract

[0138]

[0139] Table 3 Skin bilirubin content after using base material

[0140]

[0141] ② Skin color data

[0142] The skin color data are shown in Tables 4 to 11. The skin color results are shown in Figures 5 to 8 As shown by Figure 5 It can be seen that: compared with before use, after using 0.2% green leaf gall extract for 15 minutes, the skin brightness (L* value) did not change significantly; the next morning and 7 days after use, the skin brightness was significantly improved, with the improvement rates being 1.66% and 1.23% respectively. Figure 6 It can be seen that compared with before use, the skin redness (a* value) was significantly reduced after using 0.2% green leaf gall extract for 15 minutes, the next morning and 7 days, with the reduction rates being 2.71%, 4.31% and 4.19% respectively. Figure 7 It can be seen that compared with before use, the yellowness (b* value) of the skin was significantly reduced after using 0.2% green leaf gall extract for 15 minutes, the next morning and 7 days, with the reduction rates being 2.90%, 2.84% and 3.81% respectively. Figure 8 It can be seen that compared with before use, the skin ITA° value was significantly reduced the next morning and 7 days after using 0.2% green leaf gall extract, with the reduction rates being 1.81% and 1.61% respectively.

[0143] The above results show that the green leaf gall extract has the clinical effects of immediate soothing and immediate yellowing removal. At the same time, it also has the early (next morning to 7 days) clinical effects of brightening, soothing, yellowing removal and whitening.

[0144] Table 4 Skin brightness (L* value) after using 0.2% of the green leaf bile extract

[0145]

[0146]

[0147] Table 5 Skin brightness after using base material (L* value)

[0148]

[0149]

[0150] Table 6 Skin redness (a* value) after using 0.2% green leaf bile extract

[0151]

[0152] Table 7 Skin redness after using base material (a* value)

[0153]

[0154]

[0155] Table 8 Skin yellowness (b* value) after using 0.2% green leaf bile extract

[0156]

[0157]

[0158] Table 9 Yellowness of skin after using base material (b* value)

[0159]

[0160]

[0161] Table 10 Skin ITA° value after using 0.2% green leaf bile extract

[0162]

[0163]

[0164] Table 11 Skin ITA° value after using base material

[0165]

[0166]

[0167] Example 6

[0168] Formula stability test

[0169] 200g of base material (Table 1) was prepared and divided into 4 parts, and the green leaf gall extract was added to three of the base materials to make the final concentrations of 0.01wt%, 0.2wt% and 5wt%, respectively, and the other part was not treated as a blank control group. Then, the four groups of samples were placed in a constant temperature incubator at 60°C, and the appearance and smell of the two groups of samples were recorded on the 0th, 3rd, 7th, 15th and 30th days, and the pH value of the samples was measured at the same time.

[0170] The stability results are shown in Table 12. It can be seen from Table 12 that within 30 days, there was no obvious change in appearance, smell, and pH of the 0.01wt%, 0.2wt% and 5wt% green leaf gall extract groups, indicating that the green leaf gall extract has a high stability in the formula.

[0171] Table 12 Green Leaf Gallbladder Extract Stability Test Record

[0172]

[0173]

[0174] In summary, the present invention proposes for the first time the use of green leaf gall extract in whitening and / or removing yellowing. For example, green leaf gall extract can effectively inhibit the melanin production of B16-F10 cells, thereby achieving a whitening effect; in addition, green leaf gall extract can promote the expression of UGT1A1, a gene related to bilirubin metabolism in HaCaT cells, and achieves a yellowing effect by promoting bilirubin metabolism. In addition, green leaf gall extract can also reduce the bilirubin content in the skin, reduce the redness a* value and yellowness b* value of the skin, and increase the skin brightness L* value, thereby achieving a yellowing effect. In other words, green leaf gall extract can effectively solve the problems of skin pigmentation, dullness and yellowing within a safe dosage range, and has a great application prospect in the preparation of daily chemical products and / or medicines with whitening and / or yellowing effects.

[0175] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Application of a green leaf gall extract in whitening and / or removing yellowing.

2. The use according to claim 1, characterized in that: The green leaf gall extract is used to inhibit melanin production; and / or, the green leaf gall extract is used to increase the expression of UGT1A1 gene.

3. The use according to claim 1, characterized in that: The green leaf bile extract is used to reduce the bilirubin content of the skin.

4. The use according to claim 1, characterized in that: The green leaf gall extract is used to reduce the yellowness b* value of the skin.

5. The use according to claim 1, characterized in that: The green leaf bile extract is used to reduce the redness a* value of the skin.

6. The use according to claim 1, characterized in that: The green leaf bile extract is used to improve the skin brightness L* value.

7. The use according to claim 1, characterized in that: The green leaf gall extract is used for improving the ITA° value of human skin.

8. The use according to any one of claims 1 to 7, characterized in that: The effective concentration of the green leaf gall extract is 0.01wt% to 5wt%; Preferably, the effective concentration of the green leaf gall extract is 0.01wt% to 0.2wt%; Preferably, the preparation of the green leaf gall extract includes: extracting the crushed green leaf gall leaves with an organic solvent; wherein the organic solvent is an ethanol-water solution with an ethanol concentration of 65% to 75%, the dosage ratio of the organic solvent to the green leaf gall leaves is 8mL:1g to 12mL:1g, the extraction temperature is 48°C to 52°C, and the extraction time is 46h to 50h.

9. A daily chemical product, characterized in that: The daily chemical product contains green leaf gall extract; Preferably, the daily chemical products include cosmetics; Preferably, the cosmetics include skin care water, skin care milk, skin care cream, facial cleanser or hair care water; Preferably, the dosage form of the daily chemical product includes a solution, a suspension, an emulsion, a lotion, a gel, an ointment, a paste, a spray or a patch.

10. A medicine, characterized in that: The medicine contains green leaf gall extract.

Images